无症状成人脑脊液β-淀粉样蛋白阳性者的年龄加速认知下降
研究纳入392名无症状中老年人,比较脑脊液β-淀粉样蛋白(Aβ)或tau阳性者与无阿尔茨海默病(AD)相关生物标志物者的认知和海马体积轨迹。结果显示,Aβ阳性(无论tau是否升高)与更快的认知下降相关,下降模式因认知测验而异;单纯tau阳性组与生物标志物阴性组无显著差异。
要点
- 在无症状风险队列中,脑脊液Aβ升高(伴或不伴tau升高)与更快的认知下降相关。
- 临床前AD 1期和2期组在故事记忆和处理速度上呈更快的线性下降。
- 单纯tau阳性组与生物标志物阴性组在认知下降速率上无显著差异。
核心结论
- 在无症状风险队列中,脑脊液Aβ升高(伴或不伴tau升高)与更快的认知下降相关,具体下降模式因认知测验而异。
研究设计与样本
- 纵向队列研究,纳入392名已加入威斯康星阿尔茨海默病预防登记或威斯康星阿尔茨海默病研究中心的成人,完成腰椎穿刺及至少2次每两年或每年一次的神经心理评估。
- 基于78名参与者(38例痴呆,40例对照)的受试者工作特征曲线分析制定Aβ42、总tau和磷酸化tau的截断值,并应用于另外314名认知健康成人(脑脊液采集时平均年龄61.5岁)。
- 采用混合效应回归分析检验生物标志物分组与每次访视时年龄的线性和二次交互对认知和海马体积结局的影响。
主要发现
- 215名参与者(69%)为生物标志物阴性(临床前AD 0期),46名(15%)为仅Aβ阳性(临床前AD 1期),25名(8%)为Aβ阳性和tau阳性(临床前AD 2期),28名(9%)为仅tau阳性。
- 临床前AD 1期和2期组在故事记忆和处理速度测验上均表现出比0期更快的线性下降速率。
- 临床前AD 1期和2期组在列表学习和定势转换测验上表现出比0期更快的非线性下降。
- 仅tau阳性组在认知下降速率上与0期无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Compare cognitive and hippocampal volume trajectories in asymptomatic middle-aged and older adults with positive CSF markers of β-amyloid (Aβ) or tau to adults without an Alzheimer disease (AD)-associated biomarker profile. METHODS: Three hundred ninety-two adults enrolled in a longitudinal cohort study (Wisconsin Registry for Alzheimer's Prevention or Wisconsin Alzheimer's Disease Research Center) completed a lumbar puncture and at least 2 biennial or annual neuropsychological evaluations. Cutoffs for Aβ42, total tau, and phosphorylated tau were developed via receiver operating characteristic curve analyses on a sample of 78 participants (38 dementia, 40 controls). These cutoffs were applied to a separate sample of 314 cognitively healthy adults (mean age at CSF collection = 61.5 years), and mixed-effects regression analyses tested linear and quadratic interactions of biomarker group × age at each visit on cognitive and hippocampal volume outcomes. RESULTS: Two hundred fifteen participants (69%) were biomarker negative (preclinical AD stage 0), 46 (15%) were Aβ+ only (preclinical AD stage 1), 25 (8%) were Aβ+ and tau+ (preclinical AD stage 2), and 28 (9%) were tau+ only. Both stage 1 and stage 2 groups exhibited greater rates of linear decline on story memory and processing speed measures, and nonlinear decline on list-learning and set-shifting measures compared to stage 0. The tau+ only group did not significantly differ from stage 0 in rates of cognitive decline. CONCLUSION: In an asymptomatic at-risk cohort, elevated CSF Aβ (with or without elevated tau) was associated with greater rates of cognitive decline, with the specific pattern of decline varying across cognitive measures.
引用
- Clark LR, Berman SE, Norton D, et al. Age-accelerated cognitive decline in asymptomatic adults with CSF β-amyloid. Neurology. 2018. PMID: 29523644. doi:10.1212/WNL.0000000000005291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。